Suven Discovery Scientific Presentations in 2010

ACS Meeting & Exposition
August 22 - 26, 2010, Boston, MA, USA

1. New aryl sulfonamide compounds as potent and selective 5-HT6 receptor ligands.
   A. Shinde, et al.,

2. Amino aryl sulfonamides as novel and potent 5-HT6 receptor ligands.
   R. Nirogi, et al.,

37th Annual Meeting & Exposition of the Controlled Release Society (CRS)
July 10 – 14, 2010, Portland, OR, USA

3. Effect of Fillers on the Release Profile of Monolithic Dosage Formulation with HPMC as a Matrix.
   K. Kurapati et al.,

   R. Manthri et al.,

International Conference on Alzheimer’s Disease (ICAD)
July 11 - 15, 2010, Honolulu, Hawaii, USA

   I. Ahmad, et. al.,

6. The novel and selective α4β2 agonist, SUVN-911 enhances acetylcholine levels in frontoparietal cortex.
   G. Bhyrapuneni, et. al.,

7. SUVN-90121: A selective nicotinic acetylcholine receptor (nAChR) ligand for the treatment of cognitive impairment and depression.
   P. Jayarajan, et. al.,

8. SUVN-91121: A novel and selective H3 antagonist for the improvement of memory related disorders.
   V. Kandikere, et. al.,
9. In-vivo receptor occupancy for neuronal nicotinic acetylcholine $\alpha_4\beta_2$ receptors in rats using unlabelled ZW-104 as tracer
   K. Mudigonda, et. al.,

10. Preclinical investigations into the neurochemical profile of SUVN-G1031, a novel histamine H3 receptor antagonist
    V. Kandikere, et. al.,

11. Procognitive properties of SUVN-G1031, a novel selective H3 receptor antagonist in rat models of cognitive deficits
    D. Shanmuganathan, et. al.,

12. SUVN-F91201: A potent and selective nicotinic acetylcholine $\alpha_4\beta_2$ receptor agonist for the treatment of Alzheimer’s disease
    P. Jayarajan, et. al.,

13. SUVN-911: A potent and selective nicotinic acetylcholine $\alpha_4\beta_2$ receptor antagonist for the treatment of depression and other mood disorders
    R. V. Nirogi, et. al.,

14. SUVN-911: Pharmacological and safety profile of a novel and selective nicotinic acetylcholine $\alpha_4\beta_2$ receptor antagonist for the treatment of depression and other mood disorders
    G. Bhyrapuneni, et. al.,

15. Effects of SUVN-F90101, a neuronal nicotinic acetylcholine receptors agonist in animal models of neuropathic pain
    I. Ahmad, et. al.,

    R. Abraham, et. al.,

17. In-vivo brain microdialysis to study drug interaction of neuroactive compounds
    N. Muddana, et. al.,

18. Effect of fillers on the release profile of monolithic dosage formulation with HPMC as a matrix.
    D. Dogiparti, et. al.,

19. Simultaneous measurement of tele-methyl histamine and histamine levels in rat brain regions and CSF using LC-HILIC-MS/MS
    R. Poonnamaneni, et. al.,
20. *In-vivo* histamine H3 antagonist receptor occupancy assay in rats using non-radioactive tracer.
   R. Saralaya, *et. al.*, 

   K. Mudigonda, *et. al.*, 

   V. Benade, *et. al.*, 

23. Effects of selected histamine H3 receptor antagonists on tele-methylhistamine levels in rat.
   N. Muddana, *et. al.*, 

   K. Kishore, *et. al.*,